<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">Metabolic syndrome</z:e> (MS), typified by <z:hpo ids='HP_0000822'>hypertension</z:hpo>, abdominal <z:hpo ids='HP_0001513'>obesity</z:hpo>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e> and impaired <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism, is a precursor of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="50264">Thiazide</z:chebi> <z:chebi fb="40" ids="35498">diuretics</z:chebi> (TD) and beta-blockers are associated with increased risk of <z:mp ids='MP_0002055'>diabetes</z:mp> in patients with <z:hpo ids='HP_0000822'>hypertension</z:hpo>; however, the role of these agents in development of <z:mp ids='MP_0002055'>diabetes</z:mp> in MS patients is unknown </plain></SENT>
<SENT sid="2" pm="."><plain>We reviewed the literature regarding risk factors for <z:mp ids='MP_0002055'>diabetes</z:mp> development and compared this with data from the Study of Trandolapril/<z:chebi fb="1" ids="9948">Verapamil</z:chebi> SR And <z:hpo ids='HP_0000855'>Insulin Resistance</z:hpo> (STAR), which investigated the effects of two fixed-dose combinations (<z:chebi fb="17" ids="38848">FDCs</z:chebi>) [trandolapril/<z:chebi fb="1" ids="9948">verapamil</z:chebi> SR and <z:chebi fb="0" ids="6541">losartan</z:chebi>/hydrochlorothiazide (L/H)] on <z:chebi fb="105" ids="17234">glucose</z:chebi> control and new <z:mp ids='MP_0002055'>diabetes</z:mp> in MS patients </plain></SENT>
<SENT sid="3" pm="."><plain>In STAR, logistic regression modelling identified <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> A1c [odds ratio (OR) 4.21 per 1% increment; p = 0.003), L/H treatment (OR 4.04; p = 0.002) and 2-h oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test <z:chebi fb="105" ids="17234">glucose</z:chebi> levels (OR 1.39 per 10 mg/dl increments; p &lt; 0.001) as baseline predictors of <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>These data support prior analyses and suggest that choice of <z:chebi fb="0" ids="35674">antihypertensive agent</z:chebi> is important </plain></SENT>
<SENT sid="5" pm="."><plain>Patients with MS may be at lower risk of <z:mp ids='MP_0002055'>diabetes</z:mp> when using a <z:chebi fb="17" ids="38848">FDC</z:chebi> <z:chebi fb="1" ids="38215">calcium channel blocker</z:chebi> + <z:chebi fb="0" ids="35457">angiotensin-converting enzyme inhibitor</z:chebi> compared with an angiotensin receptor blocker + TD </plain></SENT>
</text></document>